EyeGate Pharmaceuticals, Inc

(NASDAQ:EYEG)

Latest On EyeGate Pharmaceuticals, Inc (EYEG):

Date/Time Type Description Signal Details
2024-05-01 05:45 ESTDividendA dividend of $0.15 has been announced on Apr 30, 2024. It will be paid May 7, 2024 with an ex-dividend date of May 1, 2024.Neutral
2024-05-01 05:45 ESTDividendA dividend of $0 has been announced on Nov 30, -0001. It will be paid May 7, 2024 with an ex-dividend date of May 1, 2024.Neutral
2024-04-01 05:45 ESTDividendA dividend of $0.16 has been announced on Mar 28, 2024. It will be paid Apr 5, 2024 with an ex-dividend date of Apr 1, 2024.Neutral
2021-08-13 13:02 ESTNewsEyegate Pharmaceuticals EPS beats by $0.07N/A
2021-08-11 00:34 ESTNewsEyeGate under pressure on launch of $10.75M direct offeringN/A
2021-07-27 09:28 ESTNewsEyeGate names Brian Strem CEO, proposes $7M Bayon dealN/A
2021-03-26 08:36 ESTNewsEyegate Pharmaceuticals misses on revenueN/A
2021-02-05 11:32 ESTAnalyst RatingThe Analyst Target Price has increased from $14.83 to $15.25.Buy
2021-01-06 20:17 ESTNewsEyeGate Pharmaceuticals announces $8M private placementN/A
2020-12-23 15:47 ESTAnalyst RatingThe Analyst Target Price has increased from $11.5 to $14.83.Buy
2020-12-21 08:09 ESTNewsEyeGate surge in premarket as it acquires Panoptes Pharma for $4MN/A
2020-12-01 11:56 ESTAnalyst RatingThe Analyst Target Price has increased from $9.75 to $11.5.Buy
2020-11-26 19:58 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 11:56 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.75 to $9.75.Neutral
2020-11-12 03:53 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 03:50 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-10 13:05 ESTNewsEyegate Pharmaceuticals EPS misses by $0.02N/A
2020-11-07 15:47 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 12:43 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:51 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 08:46 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 15:10 ESTNewsEyeGate Pharma rallies 67% on development path for conjunctivitis treatmentN/A
2020-08-09 00:42 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 17:58 ESTNewsEyegate Pharmaceuticals EPS beats by $0.05N/A
2020-08-07 08:41 ESTEarnings EstimateAn EPS average of -$0.43 is estimated for the quarter ending on September 30, 2020.Sell
2020-08-06 20:43 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 00:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-24 00:40 ESTAnalyst RatingThe Analyst Target Price has decreased from $12 to $10.75.Neutral
2020-07-23 16:59 ESTFinancialsCompany financials have been released.Neutral
2020-07-15 13:18 ESTNewsEyeGate Pharma to proceed its lead product pivotal study in dry eye diseaseN/A
2020-07-09 08:41 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 08:40 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 04:43 ESTFinancialsCompany financials have been released.Neutral
2020-06-04 19:12 ESTInsider TradeARMISTICE CAPITAL, LLC has directly acquired 12,000 shares and currently holds 1,815,500 shares.Buy
2020-06-04 19:12 ESTInsider TradeARMISTICE CAPITAL, LLC has indirectly acquired of 0 shares.Buy
2020-06-04 19:12 ESTInsider TradeARMISTICE CAPITAL, LLC has indirectly acquired of 0 shares.Buy
2020-06-04 19:12 ESTInsider TradeARMISTICE CAPITAL, LLC has directly acquired 11,000 shares and currently holds 1,803,500 shares.Buy
2020-06-04 19:12 ESTInsider TradeBrenda Mann has directly acquired 7,500 shares and currently holds 18,398 shares.Buy
2020-06-04 19:12 ESTInsider TradeMICHAEL P. MANZO has directly acquired 7,500 shares and currently holds 18,421 shares.Buy
2020-06-04 19:12 ESTInsider TradeSarah Romano has directly acquired 10,000 shares and currently holds 26,742 shares.Buy
2020-06-04 19:12 ESTInsider TradeSTEPHEN FROM has directly acquired 20,000 shares and currently holds 84,329 shares.Buy
2020-06-02 08:38 ESTAnalyst RatingThe Analyst Target Price has decreased from $90 to $12.Neutral
2020-06-02 08:38 ESTEarnings EstimateAn EPS average of -$0.43 is estimated for the quarter ending on June 30, 2020.N/A
2020-05-27 04:47 ESTFinancialsCompany financials have been released.Neutral
2020-05-08 20:43 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 04:49 ESTFinancialsCompany financials have been released.Neutral
2020-05-03 08:49 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 13:51 ESTNewsEyeGate Pharma up 71% premarket on positive dry eye dataN/A
2020-04-03 00:40 ESTFinancialsCompany financials have been released.Neutral
2020-03-22 00:37 ESTFinancialsCompany financials have been released.Neutral

About EyeGate Pharmaceuticals, Inc (EYEG):

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

EYEG Quotes by TradingView

See Advanced Chart

General

  • Name EyeGate Pharmaceuticals, Inc
  • Symbol EYEG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:15
  • Last Split Date2019-08-30
  • Fiscal Year EndDecember
  • IPO Date2015-07-31
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.eyegatepharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 7.3
  • Price/Book (Most Recent Quarter) 6.69
  • Enterprise Value Revenue 10.33
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.37
  • Return on Assets -54%
  • Return on Equity -150%
  • Earnings Per Share -$2.27
  • Revenue Per Share $0
  • Gross Profit -2203357
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 39.37 million
  • EBITDA -6660107
  • Analyst Target Price $15.25
  • Book Value Per Share $1.29
View More

Share Statistics

  • Shares Outstanding 7.04 million
  • Shares Float 2.26 million
  • % Held by Insiders 396%
  • % Held by Institutions 41.02%
  • Shares Short 24346
  • Shares Short Prior Month 37056
  • Short Ratio 0.25
View More

Technicals

  • Beta 1.16
  • 52 Week High $7.85
  • 52 Week Low $3.2
  • 50 Day Moving Average 6.29
  • 200 Day Moving Average 4.72
View More

Dividends

  • Dividend Date 2019-08-30
  • ExDividend Date N/A
  • Dividend Yield 1.95%
View More

EyeGate Pharmaceuticals, Inc (EYEG) Dividend Calendar:

EYEG's last dividend payment was made to shareholders on August 30, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

EyeGate Pharmaceuticals, Inc (EYEG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-09$N/A-$0.44-$0.42-4.76%
2020-06-302020-08-06$N/A-$0.38-$0.4311.63%
2020-03-312020-05-06$N/A-$0.43
2019-12-312020-03-04$N/A-$0.76-$0.816.17%
2019-09-302019-11-07$N/A-$1.15-$0.75-53.33%
2019-06-302019-08-08$N/A-$0.60-$0.7520%
2019-03-312019-05-08$2.69 million$0.15-$0.75120%
2018-12-312019-03-01$-314500-$0.75-$0.9016.67%
2018-09-302018-11-13$314500-$1.05-$1.136.67%
2018-06-302018-08-03$242012-$1.05-$1.9546.15%
2018-03-312018-05-11$1.1 million-$2.10-$3.5340.43%
2017-12-312018-03-02$332518-$2.25-$3.7540%
2017-09-302017-11-14$75000-$3.60-$3.30-9.09%
2017-06-302017-08-04$148000-$4.20-$2.18-93.1%
2017-03-312017-05-05$185000-$4.20-$5.2520%
2016-12-312017-02-23$160000-$5.70-$6.5512.98%
2016-09-302016-11-01$274000-$5.40-$6.6819.1%
2016-06-302016-08-10$235000-$6.90-$5.35-28.97%
2016-03-312016-05-13$N/A-$4.65-$4.55-2.2%
2015-12-312016-03-29$N/A-$3.60-$2.93-23.08%
2015-09-302015-11-12$N/A-$2.84
2015-06-302015-08-12$N/A-$3.63
2015-03-312015-05-15$N/A-$9.40

EyeGate Pharmaceuticals, Inc (EYEG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

EyeGate Pharmaceuticals, Inc (EYEG) Chart:

EyeGate Pharmaceuticals, Inc (EYEG) News:

Below you will find a list of latest news for EyeGate Pharmaceuticals, Inc (EYEG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

EyeGate Pharmaceuticals, Inc (EYEG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

EyeGate Pharmaceuticals, Inc (EYEG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920077470/0001104659-20-077470-index.htm
2020-02-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920007189/0001104659-20-007189-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920011314/0001104659-20-011314-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920011324/0001104659-20-011324-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920011330/0001104659-20-011330-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920011342/0001104659-20-011342-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022838/0001104659-20-022838-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022841/0001104659-20-022841-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022843/0001104659-20-022843-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022844/0001104659-20-022844-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022845/0001104659-20-022845-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022846/0001104659-20-022846-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022847/0001104659-20-022847-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022848/0001104659-20-022848-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920022849/0001104659-20-022849-index.htm
2020-03-0410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/0001104659-20-029162-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920031496/0001104659-20-031496-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920031497/0001104659-20-031497-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920031498/0001104659-20-031498-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920031499/0001104659-20-031499-index.htm
2020-03-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920037762/0001104659-20-037762-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920040798/0001104659-20-040798-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920043261/0001104659-20-043261-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920043262/0001104659-20-043262-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920043263/0001104659-20-043263-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920043264/0001104659-20-043264-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920048224/0001104659-20-048224-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920053380/0001104659-20-053380-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1372514/000110465920053393/0001104659-20-053393-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1372514/000110465920057438/0001104659-20-057438-index.htm
2020-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920057468/0001104659-20-057468-index.htm
2020-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920057471/0001104659-20-057471-index.htm
2020-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920057472/0001104659-20-057472-index.htm
2020-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920057474/0001104659-20-057474-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920067975/0001104659-20-067975-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920069822/0001104659-20-069822-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920069823/0001104659-20-069823-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920069824/0001104659-20-069824-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920069826/0001104659-20-069826-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920077470/0001104659-20-077470-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920081219/0001104659-20-081219-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920081223/0001104659-20-081223-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920081225/0001104659-20-081225-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920081227/0001104659-20-081227-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920090917/0001104659-20-090917-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920090918/0001104659-20-090918-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920090919/0001104659-20-090919-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920090920/0001104659-20-090920-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1372514/000110465920091445/0001104659-20-091445-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920091458/0001104659-20-091458-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920102296/0001104659-20-102296-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920102298/0001104659-20-102298-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920102299/0001104659-20-102299-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920102300/0001104659-20-102300-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1372514/000110465920104579/0001104659-20-104579-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920112300/0001104659-20-112300-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920112301/0001104659-20-112301-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920112302/0001104659-20-112302-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920112303/0001104659-20-112303-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920120949/0001104659-20-120949-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920120953/0001104659-20-120953-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920120954/0001104659-20-120954-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1372514/000110465920120955/0001104659-20-120955-index.htm
2020-08-0525-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1372514/000135445720000385/0001354457-20-000385-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1372514/000139382520000038/0001393825-20-000038-index.htm

EyeGate Pharmaceuticals, Inc (EYEG) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyeGate Pharmaceuticals, Inc (EYEG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 396%
Institutional Ownership: 4102%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-06ARMISTICE CAPITAL, LLCDirectorBuy0.001,803,500.00https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm
2020-02-06ARMISTICE CAPITAL, LLCDirectorBuy11,000.006.1867,980.001,803,500.00https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm
2020-02-10ARMISTICE CAPITAL, LLCDirectorBuy0.001,815,500.00https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm
2020-02-10ARMISTICE CAPITAL, LLCDirectorBuy12,000.006.0472,480.001,815,500.00https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm
2020-02-14Brenda MannVP of Research & DevelopmentBuy7,500.0018,398.00https://www.sec.gov/Archives/edgar/data/1372514/000110465920022841/0001104659-20-022841-index.htm
2020-02-14MICHAEL P. MANZOVP of EngineeringBuy7,500.0018,421.00https://www.sec.gov/Archives/edgar/data/1372514/000110465920022843/0001104659-20-022843-index.htm
2020-02-14Sarah RomanoChief Financial OfficerBuy10,000.0026,742.00https://www.sec.gov/Archives/edgar/data/1372514/000110465920022848/0001104659-20-022848-index.htm
2020-02-14STEPHEN FROMPresident and CEOBuy20,000.0084,329.00https://www.sec.gov/Archives/edgar/data/1372514/000110465920022849/0001104659-20-022849-index.htm